Patent · US Active

Recombinant erIL-15 NK cells

US11364265B1 · kind B1 · utility

0Cited by

1References

20Claims

0Family size

Assignees

NantCell, Inc. · US
NantBio, Inc. · US
ImmunityBio, Inc. · US

Inventors

Patrick Soon-Shiong · Los Angeles, US
Shahrooz Rabizadeh · Culver City, US
Kayvan Niazi · Los Angeles, US
Hans G. Klingemann · Culver City, US

Key dates

Filing date	Feb 27, 2020
Grant date	Jun 21, 2022
Priority date	—
Expiry date	Feb 27, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2510/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Systems and methods are presented that provide for improved NK cell function. In preferred aspects, NK-92 cells express recombinant er/LSP-IL-15 to so render the NK-92 cells independent of exogenous cytokines and to provide extracellular immune stimulation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.